Paratek Pharmaceuticals (FRA:N4CN) Debt-to-Asset : 1.78 (As of Jun. 2023)

Paratek Pharmaceuticals Debt-to-Asset Chart

Paratek Pharmaceuticals Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
Debt-to-Asset		Get a 7-Day Free Trial					0.76	1.05	1.43	1.39	1.50

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Asset	Get a 7-Day Free Trial															1.58	1.65	1.50	1.72	1.78

Competitive Comparison of Paratek Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Paratek Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paratek Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Debt-to-Asset falls into.

Paratek Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Paratek Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Paratek Pharmaceuticals's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paratek Pharmaceuticals  (FRA:N4CN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Paratek Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (FRA:N4CN) Business Description